|
If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | |||||||||||
  Diabetic MedicineVolume 25 Issue 5, Pages 625 - 626 Published Online: 28 Jun 2008 Journal compilation © 2010 Diabetes UK
Abstract | References | Full Text: HTML, PDF (Size: 80K) | Related Articles | Citation Tracking  Case Report Varenicline may trigger severe hypoglycaemia in Type 1 diabetes Copyright Journal compilation © 2008 Diabetes UK KEYWORDS hypoglycaemia • smoking cessation • Type 1 diabetes • varenicline Diabet. Med. 25, 625–626 (2008) ABSTRACT
Background Varenicline is a new drug indicated for smoking cessation. It has primarily been investigated in healthy adults. The commonest side-effects are nausea, headache, sleep disturbance, constipation, flatulence and vomiting. Hypoglycaemia has not been reported. As smoking cessation is important to reduce risk of cardiovascular morbidity, especially in diabetes, use of effective drugs indicated for smoking cessation is rational. Case report We report multiple episodes of severe hypoglycaemia after starting varenicline in a 53-year-old woman with Type 1 diabetes. Since onset of diabetes at age 25 years and until start of varenicline therapy, she had only experienced one episode of severe hypoglycaemia and hypoglycaemia awareness was not impaired. The severe hypoglycaemic episodes disappeared after withdrawal of varenicline. Conclusions We recommend cautious prescription of varenicline, intensified blood glucose monitoring and careful education of patients with diabetes treated with varenicline. Further investigation of the use of varenicline in patients with diabetes is warranted. Accepted 24 January 2008 | 
|
